Relative contraindications requiring careful consideration and enhanced medical supervision include history of pancreatitis, severe gastrointestinal disease including gastroparesis, diabetic retinopathy (requires ophthalmologic monitoring during therapy), severe kidney disease, history of suicidal ideation or severe depression, gallbladder disease or history of cholecystitis, and age under 18 years
Its important to remember that most people never experience these issues
Was the injection of unlabeled B12 done at the right time
NG: Writing review & editing, Resources, Writing original draft
Composition GHK-Cu: 50 mg BPC-157: 10 mg TB-500 (Thymosin Beta 4): 10 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Combined evaluation of copper peptide, BPC-157, and TB-500 in in-vitro or ex-vivo assay systems Assay development, including chromatographic separation of three co-formulated peptides Stability characterization of a three-analyte lyophilized blend under laboratory storage conditions Method documentation for HPLC/LC-MS identity and purity assessments Documentation Analysis Report Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
The NICE Guideline NG239 (2024) and the AAFP clinical review both support this approach